Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Hydrocortisone × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Leukemia, Biphenotypic, Acute 5 Prostatic Neoplasms 4 Burkitt Lymphoma 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Leukemia, Myeloid, Acute 2 Stomach Neoplasms 1 Sarcoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Pancreatitis 1 Pancreatic Neoplasms 1 Pancreatic Intraductal Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia 1 Hodgkin Disease 1 Hematopoietic and Lymphatic System Neoplasm 1 Glioblastoma 1 Fistula 1 Duodenal Neoplasms 1 Drug-Related Side Effects and Adverse Reactions 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Radiosurgery 3 Prednisone 2 Docetaxel 2 Androgen Antagonists 2 Abiraterone Acetate 2 fludrocortisone acetate 1 enzalutamide 1 apalutamide 1 Standard of Care 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡